Hidden Ral-CTSA pathway lets dietary cholesterol erode liver LDL receptors, and blocking it lowers LDL
UC San Diego researchers found a Ral–cathepsin A pathway that depletes liver LDL receptors, and an inhibitor already safety-tested in humans lowered LDL in mice.
Summary
High cholesterol is a major driver of heart disease, the world's leading cause of death. Researchers at UC San Diego School of Medicine have uncovered a hidden pathway explaining why eating a lot of cholesterol weakens the liver's ability to clear LDL, the so-called bad cholesterol. In mice and human cells, dietary cholesterol activated a protein called Ral. Ral set off a chain of events involving an enzyme called cathepsin A (CTSA), which led to the loss of LDL receptors, the docking stations on liver cells that pull LDL from the blood. When the team blocked CTSA with a small-molecule inhibitor, LDL receptors became more stable and circulating LDL fell sharply in mice. The experimental drug has already passed an early human safety trial, which could speed development. The work, published in Nature, is preclinical, so it is not yet a treatment people can use, but it points to a new route beyond statins and PCSK9 inhibitors.
Detailed Summary
Heart disease tied to high cholesterol remains the leading cause of death worldwide. Despite more treatment options than ever, many people still fail to reach safe LDL levels, and others cannot tolerate side effects of current drugs. Understanding why the body's cholesterol clearance falters therefore matters for anyone interested in protecting cardiovascular healthspan.
Researchers at the University of California San Diego School of Medicine, led by Alan Saltiel, PhD, have identified a previously unknown pathway behind this problem. The liver clears LDL cholesterol using LDL receptors on the surface of its cells, which capture LDL from the blood and bring it inside for processing. More receptors mean more LDL removed. Statins and PCSK9 inhibitors work largely by preserving or increasing receptor numbers.
Using mice and human cells, the team found that high dietary cholesterol activates a protein called Ral, which Saltiel had previously studied in fat cells. Active Ral triggers a chain of events that depletes LDL receptors. The researchers then identified an enzyme, cathepsin A (CTSA), as a critical piece of the process that drives receptor loss. Blocking CTSA with a small-molecule inhibitor made LDL receptors more stable, and circulating LDL cholesterol dropped dramatically in mice. An experimental drug targeting this pathway has already completed an early human safety trial, which could shorten the path to clinical testing.
The practical implication is a potential new class of LDL-lowering therapy that works through a different mechanism than existing drugs. It might eventually help people who do not reach targets on statins or PCSK9 inhibitors, or who cannot tolerate them. The work also reinforces a familiar message that diet high in cholesterol can blunt the liver's own defenses.
The caveats are significant. Most of the efficacy data come from mice, and an early safety trial does not show that the drug lowers LDL in people. Dose, long-term safety, effects on cardiovascular events and how it compares with or adds to current therapies remain unknown. Readers should not change any treatment based on this preclinical result.
Key Findings
- Dietary cholesterol activates the protein Ral, which sets off a chain of events that reduces LDL receptors on liver cells.
- The enzyme cathepsin A (CTSA) helps drive the loss of LDL receptors in this newly identified pathway.
- Blocking CTSA with a small-molecule inhibitor stabilized LDL receptors and sharply lowered circulating LDL cholesterol in mice.
- An experimental drug targeting the pathway has already passed an early human safety trial, which may speed development.
- The study used mice and human cells and was published in Nature; efficacy in people is untested.
Methodology
This is a news report summarizing a peer-reviewed study in Nature from UC San Diego School of Medicine, distributed via ScienceDaily. The evidence base is preclinical, using mouse experiments and human cells, plus a reference to an earlier human safety trial of the drug. The excerpt is truncated, so full methods and numerical results are not visible.
Study Limitations
Efficacy data come from mice and cell models, which often fail to translate to humans, and the early human trial only assessed safety. The article gives no effect sizes, dosing, or data on cardiovascular outcomes, and the text is cut off mid-sentence. Check the Nature paper for the specific inhibitor, magnitude of LDL reduction, and any safety signals.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: